Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Mar. 13 reported its financial and operational results for the fourth quarter and year ended December 31, 2013. Net loss applicable to common stockholders for the three months ended December 31, 2013 was $6.4 million, or $0.10 per diluted share, compared to a net loss applicable to common stockholders of $6.5 million, or $0.24 per diluted share, for the same period in 2012. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares after opening at $6.16 moved to $6.87 on last trade day and at the end of the day closed at $6.59. Company price to sales ratio in past twelve months was calculated as 6410.53 and price to cash ratio as 7.79. Idera Pharmaceuticals Inc (NASDAQ:IDRA) showed a positive weekly performance of 14.41%.
Durata Therapeutics (NASDAQ:DRTX) shares reached a new 52-week high during trading on Tuesday after Jefferies Group raised their price target on the stock from $10.00 to $12.40, Analyst Ratings Networkreports. Durata Therapeutics Inc (NASDAQ:DRTX) shares advanced 5.39% in last trading session and ended the day on $14.66. DRTX return on equity ratio is recorded as -133.70% and its return on assets is -60.40%. Durata Therapeutics Inc (NASDAQ:DRTX) yearly performance is 67.73%.
IGI Laboratories Inc (NYSEMKT:IG) announced that the U.S. Food and Drug Administration has approved of its new drug, abbreviated as ANDA. IGI Laboratories, Inc. (NYSEMKT:IG) shares moved up 9.96% in last trading session and was closed at $5.85 while trading in range of $5.26 – $5.87 – IGI Laboratories, Inc. (NYSEMKT:IG) year to date (YTD) performance is 91.80%.
Albany Molecular Research (NASDAQ:AMRI) was upgraded by analysts at TheStreet from a hold rating to a buy rating. The analysts wrote, “Albany Molecular Research (AMRI) has been upgraded by TheStreet Ratings from hold to buy. Albany Molecular Research, Inc. (NASDAQ:AMRI) weekly performance is 25.24%. On last trading day company shares ended up $19.55. Albany Molecular Research, Inc. (NASDAQ:AMRI) distance from 50-day simple moving average (SMA50) is 52.20%. Analysts mean target price for the company is $13.00.